한글목차

펩티드 약물 복합체 시장 규모는 최근 급성장하고 있습니다. 2025년 36억 4,000만 달러에서 2026년에는 42억 1,000만 달러에 이르고, CAGR 15.4%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 펩타이드 화학의 발전, 기존 화학요법의 한계, 종양학 분야의 의약품 연구 증가, 표적치료제 플랫폼의 확대, 생물학적 제제 제조의 성장에 기인한 것으로 분석됩니다.

펩티드 약물 복합체 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 74억 4,000만 달러에 이르고, CAGR은 15.3%를 나타낼 전망입니다. 예측 기간 동안의 성장은 정밀의료 수요 증가, 링커 기술의 발전, 암 적응증 확대, 펩타이드 의약품 개발 투자 증가, 진단용 표적 결합체의 성장에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 표적 펩타이드 결합체 개발 확대, 종양 치료 분야에서의 사용 증가, 약물 선택성 향상에 대한 집중, 진단용 펩타이드 결합체 확대, 신규 결합체 관련 임상시험 증가 등을 꼽을 수 있습니다.

개인 맞춤형 치료에 대한 수요 증가는 향후 몇 년 동안 펩타이드 약물 복합체 시장의 성장을 가속할 것으로 예측됩니다. 맞춤 치료란 최적의 치료 결과를 얻기 위해 개인의 특정 유전자 프로파일, 생활습관, 질병 특성에 맞게 설계된 의료 요법입니다. 유전체학의 발전으로 개별 질병 마커의 식별이 가능해져 보다 정확하고 효과적인 치료가 가능해짐에 따라 개인별 맞춤 치료의 도입이 증가하고 있습니다. 맞춤 치료는 환자의 특정 질병 바이오마커에 결합하는 표적 펩타이드의 선택을 가능하게 하고, 약물 전달의 정확성과 효율성을 향상시킴으로써 펩타이드 약물 복합체를 지원합니다. 예를 들어, 2024년 2월 미국 비영리단체인 '맞춤의료연합'이 발표한 보고서에 따르면, 2023년 FDA는 희귀질환 환자를 위한 16건의 신규 맞춤치료제를 승인했는데, 이는 2022년 6건보다 크게 증가한 수치입니다. 따라서 개인 맞춤형 치료에 대한 수요 증가가 펩타이드 약물 복합체 시장의 성장을 견인할 것으로 예측됩니다.

펩타이드 약물 복합체 시장에서 사업을 전개하는 주요 기업들은 치료 정확도를 높이기 위해 종양 선택적 펩타이드 약물 복합체와 같은 첨단 치료 옵션 개발에 주력하고 있습니다. 종양 선택적 펩타이드 약물 복합체는 암세포에 선택적으로 결합하도록 설계된 펩타이드를 이용한 표적치료제로, 건강한 조직의 손상을 최소화하면서 세포독성 약물을 종양에 직접 전달할 가능성이 있습니다. 예를 들어, 2025년 3월, 미국에 본사를 둔 종양학 생명공학 기업 Cybrexa Therapeutics는 자사의 알파렉스 기술에 대한 새로운 전임상 데이터를 보고했습니다. 이 데이터는 Cybrexa의 항원 독립적 펩타이드 약물 복합체(PDC) 플랫폼이 강력한 마이크로튜브 억제제를 종양 세포에 특이적으로 전달할 수 있음을 입증했습니다. 이 전략은 종양의 성장을 효과적으로 억제하고 지속적인 항종양 면역반응을 유발합니다. 이번 결과는 사이브렉사의 기술이 암 치료 성과를 향상시킬 수 있는 가능성을 보여줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Peptide drug conjugates are targeted treatment approaches that link peptides with cytotoxic agents to enhance therapeutic accuracy. The peptide component binds selectively to specific cell receptors and is connected to the drug, allowing direct targeting of diseased cells such as tumors. This strategy enhances drug stability, selectivity, and bioavailability, thereby improving overall treatment efficacy while reducing harm to healthy tissues.

The primary categories of peptide drug conjugates are therapeutic and diagnostic. A peptide drug conjugate therapeutic involves attaching a peptide to a drug, typically a cytotoxic compound, to deliver the drug directly to cancer cells or other affected tissues. These therapies are applied in oncology, immunology, infectious diseases, and other areas, and may be administered via intravenous, subcutaneous, or other routes. They are utilized by a range of end users, including hospitals, clinics, pharmacies, and others.

Tariffs have impacted the peptide drug conjugates market by increasing costs of imported peptide synthesis equipment, cytotoxic payloads, and conjugation materials. These impacts are most pronounced in oncology-focused applications across North America, Europe, and Asia-Pacific. Higher tariffs have raised development costs. However, tariffs have encouraged localized manufacturing and strengthened regional biopharma capabilities.

The peptide drug conjugates market research report is one of a series of new reports from The Business Research Company that provides peptide drug conjugates market statistics, including peptide drug conjugates industry global market size, regional shares, competitors with a peptide drug conjugates market share, detailed peptide drug conjugates market segments, market trends and opportunities, and any further data you may need to thrive in the peptide drug conjugates industry. This peptide drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide drug conjugates market size has grown rapidly in recent years. It will grow from $3.64 billion in 2025 to $4.21 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to advancements in peptide chemistry, limitations of conventional chemotherapy, increased oncology drug research, expansion of targeted therapy platforms, growth of biologics manufacturing.

The peptide drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to rising demand for precision therapies, advancements in linker technologies, expansion of cancer indications, increased investment in peptide drug development, growth of diagnostic-targeted conjugates. Major trends in the forecast period include growing development of targeted peptide conjugates, increasing use in oncology therapeutics, rising focus on improved drug selectivity, expansion of diagnostic peptide conjugates, increasing clinical trials for novel conjugates.

The increasing demand for personalized treatments is expected to propel the growth of the peptide drug conjugates market in the coming years. Personalized treatments are medical therapies designed to suit an individual's specific genetic profile, lifestyle, and disease characteristics to achieve optimal outcomes. The adoption of personalized treatments is rising due to advancements in genomics that enable the identification of individual disease markers, resulting in more accurate and effective therapies. Personalized treatments support peptide drug conjugates by enabling the selection of targeted peptides that bind to specific disease biomarkers in patients, improving the precision and efficiency of drug delivery. For example, in February 2024, a report published by the Personalized Medicine Coalition, a US-based non-profit organization, stated that the FDA approved 16 novel personalized medicines for patients with rare diseases in 2023, a significant increase from the 6 approvals in 2022. Consequently, the growing demand for personalized treatments is expected to drive the expansion of the peptide drug conjugates market.

Leading companies operating in the peptide drug conjugates market are concentrating on the development of advanced therapeutic options, such as tumor-selective peptide drug conjugates, to improve treatment accuracy. Tumor-selective peptide drug conjugates are targeted therapies that employ peptides engineered to selectively bind to cancer cells, allowing cytotoxic agents to be delivered directly to tumors while minimizing harm to healthy tissues. For example, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, reported new preclinical data related to its alphalex technology. The data demonstrated the effectiveness of Cybrexa's antigen-agnostic peptide-drug conjugate (PDC) platform in delivering potent microtubule inhibitors specifically to tumor cells. This strategy successfully inhibits tumor growth and triggers a sustained anti-tumor immune response. The results highlight the potential of Cybrexa's technology to advance cancer treatment outcomes.

In May 2023, Bayer AG, a Germany-based pharmaceutical company, entered into a partnership with Bicycle Therapeutics to develop radioconjugates targeting multiple oncology indications. Under the collaboration, Bicycle will apply its phage display platform to identify highly selective bicyclic peptides. Bayer will oversee the progression of these candidates through preclinical and clinical development, in addition to handling manufacturing and commercialization efforts, with the aim of providing targeted radiotherapy solutions for unmet needs in oncology. Bicycle Therapeutics is a UK-based producer of peptide drug conjugates.

Major companies operating in the peptide drug conjugates market are PeptiDream Incorporated, Cybrexa Therapeutics Inc., Oncopeptides Aktiebolag (AB), Soricimed Biopharma Inc., Angiochem Inc., ADC Therapeutics SA, Ambrx Inc., Araris Biotech AG, Adcytherix SA, ProteinQure Incorporated, Esperance Pharmaceuticals Inc., Protagonist Therapeutics Inc., PepGen Corporation, Curium US LLC, AstraZeneca PLC, Novartis AG, Italfarmaco Societa per Azioni, BioNTech SE, Theratechnologies Inc., Zealand Pharma A/S

North America was the largest region in the peptide drug conjugates market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide drug conjugates market consists of revenues earned by entities by providing services such as conjugation services, preclinical testing, formulation development, target discovery, and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide drug conjugates market also includes sales of peptide payload linkers, synthetic peptides, peptide targeting ligands, and drug delivery systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Drug Conjugates Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Therapeutic; Diagnostic
• 2) By Therapy Area: Oncology; Immunology; Infectious Diseases; Other Therapy Areas
• 3) By Route of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
• 4) By End User: Hospitals; Clinics; Pharmacies; Other End Users
• Subsegments:
• 1) By Therapeutic: Monoclonal Antibodies (mAbs); Cytotoxic Agents; Immunomodulatory Agents; Targeted Therapies
• 2) By Diagnostic: Imaging Agents; Biomarker Targeting Agents
• Companies Mentioned: PeptiDream Incorporated; Cybrexa Therapeutics Inc.; Oncopeptides Aktiebolag (AB); Soricimed Biopharma Inc.; Angiochem Inc.; ADC Therapeutics SA; Ambrx Inc.; Araris Biotech AG; Adcytherix SA; ProteinQure Incorporated; Esperance Pharmaceuticals Inc.; Protagonist Therapeutics Inc.; PepGen Corporation; Curium US LLC; AstraZeneca PLC; Novartis AG; Italfarmaco Societa per Azioni; BioNTech SE; Theratechnologies Inc.; Zealand Pharma A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Peptide Drug Conjugates Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Peptide Drug Conjugates Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Peptide Drug Conjugates Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Peptide Drug Conjugates Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growing Development Of Targeted Peptide Conjugates
  • 4.2.2 Increasing Use In Oncology Therapeutics
  • 4.2.3 Rising Focus On Improved Drug Selectivity
  • 4.2.4 Expansion Of Diagnostic Peptide Conjugates
  • 4.2.5 Increasing Clinical Trials For Novel Conjugates

5. Peptide Drug Conjugates Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Research Institutes
• 5.4 Pharmaceutical Companies
• 5.5 Diagnostic Centers

6. Peptide Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Peptide Drug Conjugates Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Peptide Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Peptide Drug Conjugates Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Peptide Drug Conjugates Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Peptide Drug Conjugates Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Peptide Drug Conjugates Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Peptide Drug Conjugates Market Segmentation

• 9.1. Global Peptide Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Therapeutic, Diagnostic
• 9.2. Global Peptide Drug Conjugates Market, Segmentation By Therapy Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Immunology, Infectious Diseases, Other Therapy Areas
• 9.3. Global Peptide Drug Conjugates Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Subcutaneous, Other Routes Of Administration
• 9.4. Global Peptide Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Pharmacies, Other End Users
• 9.5. Global Peptide Drug Conjugates Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies (mAbs), Cytotoxic Agents, Immunomodulatory Agents, Targeted Therapies
• 9.6. Global Peptide Drug Conjugates Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Imaging Agents, Biomarker Targeting Agents

10. Peptide Drug Conjugates Market Regional And Country Analysis

• 10.1. Global Peptide Drug Conjugates Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Peptide Drug Conjugates Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Peptide Drug Conjugates Market

• 11.1. Asia-Pacific Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Peptide Drug Conjugates Market

• 12.1. China Peptide Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Peptide Drug Conjugates Market

• 13.1. India Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Peptide Drug Conjugates Market

• 14.1. Japan Peptide Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Peptide Drug Conjugates Market

• 15.1. Australia Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Peptide Drug Conjugates Market

• 16.1. Indonesia Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Peptide Drug Conjugates Market

• 17.1. South Korea Peptide Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Peptide Drug Conjugates Market

• 18.1. Taiwan Peptide Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Peptide Drug Conjugates Market

• 19.1. South East Asia Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Peptide Drug Conjugates Market

• 20.1. Western Europe Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Peptide Drug Conjugates Market

• 21.1. UK Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Peptide Drug Conjugates Market

• 22.1. Germany Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Peptide Drug Conjugates Market

• 23.1. France Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Peptide Drug Conjugates Market

• 24.1. Italy Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Peptide Drug Conjugates Market

• 25.1. Spain Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Peptide Drug Conjugates Market

• 26.1. Eastern Europe Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Peptide Drug Conjugates Market

• 27.1. Russia Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Peptide Drug Conjugates Market

• 28.1. North America Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Peptide Drug Conjugates Market

• 29.1. USA Peptide Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Peptide Drug Conjugates Market

• 30.1. Canada Peptide Drug Conjugates Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Peptide Drug Conjugates Market

• 31.1. South America Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Peptide Drug Conjugates Market

• 32.1. Brazil Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Peptide Drug Conjugates Market

• 33.1. Middle East Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Peptide Drug Conjugates Market

• 34.1. Africa Peptide Drug Conjugates Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Peptide Drug Conjugates Market, Segmentation By Type, Segmentation By Therapy Area, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Peptide Drug Conjugates Market Regulatory and Investment Landscape

36. Peptide Drug Conjugates Market Competitive Landscape And Company Profiles

• 36.1. Peptide Drug Conjugates Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Peptide Drug Conjugates Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Peptide Drug Conjugates Market Company Profiles
  • 36.3.1. PeptiDream Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Cybrexa Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Oncopeptides Aktiebolag (AB) Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Soricimed Biopharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Angiochem Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Peptide Drug Conjugates Market Other Major And Innovative Companies

• ADC Therapeutics SA, Ambrx Inc., Araris Biotech AG, Adcytherix SA, ProteinQure Incorporated, Esperance Pharmaceuticals Inc., Protagonist Therapeutics Inc., PepGen Corporation, Curium US LLC, AstraZeneca PLC, Novartis AG, Italfarmaco Societa per Azioni, BioNTech SE, Theratechnologies Inc., Zealand Pharma A/S

38. Global Peptide Drug Conjugates Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Peptide Drug Conjugates Market

40. Peptide Drug Conjugates Market High Potential Countries, Segments and Strategies

• 40.1 Peptide Drug Conjugates Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Peptide Drug Conjugates Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Peptide Drug Conjugates Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer